Atxn2 Rna Interference Agents

Abstract: Provided herein are ATXN2 RNAi agents and compositions comprising an ATXN2 RNAi agent. Also provided herein are methods of using the ATXN2 RNAi agents or compositions comprising an ATXN2 RNAi agent for reducing ATXN2 expression, and/or treating ATXN2-associated neurological disease in a subject.

Patent Information

Application #

Filing Date

10 January 2025

Publication Number

08/2025

Publication Type

INA

Invention Field

BIOTECHNOLOGY

Status

Email

Parent Application

Applicants

ELI LILLY AND COMPANY

Lilly Corporate Center Indianapolis, Indiana 46285

Inventors

1. MCCARTHY, Andrew Peter

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288

2. TANI, Hiroaki

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288

3. YORK, Jeremy, S.

c/o Eli Lilly and Company P.O. Box 6288 Indianapolis, Indiana 46206-6288

Specification

Documents

Application Documents

#	Name	Date
1	202517002367-STATEMENT OF UNDERTAKING (FORM 3) [10-01-2025(online)].pdf	2025-01-10
3	202517002367-Sequence Listing in PDF [10-01-2025(online)].pdf	2025-01-10
4	202517002367-REQUEST FOR EXAMINATION (FORM-18) [10-01-2025(online)].pdf	2025-01-10
5	202517002367-POWER OF AUTHORITY [10-01-2025(online)].pdf	2025-01-10
6	202517002367-FORM-26 [10-01-2025(online)].pdf	2025-01-10
7	202517002367-FORM 18 [10-01-2025(online)].pdf	2025-01-10
8	202517002367-FORM 1 [10-01-2025(online)].pdf	2025-01-10
9	202517002367-DECLARATION OF INVENTORSHIP (FORM 5) [10-01-2025(online)].pdf	2025-01-10
10	202517002367-COMPLETE SPECIFICATION [10-01-2025(online)].pdf	2025-01-10
11	202517002367-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [10-01-2025(online)].pdf	2025-01-10
12	202517002367-Proof of Right [24-06-2025(online)].pdf	2025-06-24
13	202517002367-FORM 3 [24-06-2025(online)].pdf	2025-06-24